ClinicalTrials.gg
CompletedNCT03405155Updated Jul 16, 2026Results posted

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

A Phase 2 interventional study of Nivolumab in Melanoma (Skin), sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
92nd of 142
26 · median 50
Started
2018
with 7 others
Phase 2
76 of 142
18 open now
Registered
55th of 142
by date

Among the 142 studies testing nivolumab in Melanoma, this one is the 92nd largest by enrollment, is one of 8 that started in 2018, is one of 76 in phase 2, and was the 55th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the efficacy nivolumab administered in the adjuvant setting in patients with resected stage IIB or stage IIC cutaneous melanoma.

SECONDARY OBJECTIVES:

I. To evaluate and estimate the median duration of overall survival (OS) in stage IIB-IIC melanoma patients.

II. To evaluate and estimate the median duration of distant metastases-free survival (DMFS) in stage IIB-IIC melanoma patients.

III. To assess safety and toxicity using Common Terminology Criteria for Adverse Events (CTCAE) version (V)5.

IV. To assess quality of life using the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) quality of life instrument.

TERTIARY OBJECTIVES:

I. To assess and compare clinical, histological, immunological and molecular panels as prognostic and predictive biomarkers.

03

Conditions studied

  • Melanoma (Skin)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have completely resected (as per standard of care) melanoma of cutaneous origin in order to be eligible for this study; patients must be classified as stage IIB or IIC cutaneous melanoma using the American Joint Committee on Cancer eighth edition; patients with melanoma of mucosal or other non-cutaneous origin are not eligible; patients with melanoma of ocular origin are not eligible
  • Patients must have a negative sentinel lymph node or undergo a failed attempt at sentinel lymph node biopsy including lymphoscintography which fails to show a sentinel lymph node from the melanoma primary site
  • Patients must have systemic cross-sectional imaging (positron emission tomography [PET]/computed tomography [CT] or CT of chest, abdomen, and pelvis) which shows no evidence of disease
  • Patient must be able to comprehend and sign a written and be willing to comply with all study procedures
  • Patients must have an (ECOG) performance status of 0 or 1
  • (ANC) >= 1,500 microliter (mcL)
  • >= 100,000/mcL
  • >= 10 g/dL
  • Total =\< 1.5 x institutional (IULN) (except Gilbert's syndrome, who must have a total bilirubin \< 3.0 mg/dL)
  • Serum glutamic-oxaloacetic transaminase () (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and alkaline phosphatase =\< 2 x institutional upper limit of normal (IULN)
  • Serum creatinine =\< 1.5xULN OR measured or calculated >= 60 mL/min
  • Patients known to be (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate (>= 350 mm\^3), and serum HIV viral load of \< 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
  • Women of must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of must have agreed to use an effective method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursing
  • Therapy must be initiated within 120 days of surgical resection of the sentinel lymph nodes and within 6 months of initial diagnosis.
  • Patients must be willing to have archived tumor specimens utilized for correlative studies if available
  • Patients must not have known active virus (HBV) or virus (HCV) infection prior to registration

Exclusion criteria

Exclusion Criteria:

  • No other prior is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, lobular carcinoma of the breast in situ, atypical melanocytic hyperplasia or melanoma in situ, adequately treated stage I or II cancer (including multiple primary melanomas) from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
  • Current therapy including > 10 mg/day of prednisone within 14 days of enrollment is not permitted; inhaled or topical , and adrenal replacement steroid doses =\< 10 mg daily prednisone equivalent, are permitted in the absence of active disease
  • Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Patients must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Patients must not have received within 42 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
  • Patients must not have a history or current evidence of any condition, therapy or laboratory abnormality that might confound the trial results, interfere with the patient's participation for the full duration of the trial, or indicate that participation in the trial is not in the patient's best interests, in the opinion of the treating investigator
  • Patients must not be pregnant or lactating
  • Prior therapy with , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not permitted
  • Treatment with any agent within 14 days of first administration of study treatment is not permitted
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment (nivolumab)

    Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, NIVO, Opdivo, ONO-4538

06

What researchers measure

Primary outcomes

  1. Recurrence-free Survival

    Kaplan-Meier estimate of the percentage of participants who were recurrence-free at approximately 2 years after treatment initiation.

    Time frame: Approximately 22 months (2 years)

Secondary outcomes

  1. Overall Survival

    Overall Survival (OS) is defined as time from study entry until death from any cause. OS will be determined, as will the cumulative percentage of patients remaining progression-free/alive at selected time points after initial treatment at 24 months

    Time frame: Up to 24 months

  2. Cumulative Percentage of Patients Remaining Distant Metastases-Free/Alive at 1yr and 2yrs After Initial Treatment

    The cumulative percentage of patients remaining distant metastases-free/alive at 1yr and 2yrs after initial treatment

    Time frame: Up to 24 months

  3. Number of Adverse Events

    Adverse events will be graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Up to 24 months

07

Results

Posted Jun 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Nivolumab)
Started26
Completed18
Not completed8
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up1

Outcome measures

PrimaryRecurrence-free Survival

Kaplan-Meier estimate of the percentage of participants who were recurrence-free at approximately 2 years after treatment initiation.

Time frame:
Approximately 22 months (2 years)
Reported as:
Number · percentage of participants
Recurrence-free Survival
percentage of participantsTreatment (Nivolumab)
Recurrence-free Survival87.8 (64.2 to 96.3)
SecondaryOverall Survival

Overall Survival (OS) is defined as time from study entry until death from any cause. OS will be determined, as will the cumulative percentage of patients remaining progression-free/alive at selected time points after initial treatment at 24 months

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsTreatment (Nivolumab)
Overall Survival26
SecondaryCumulative Percentage of Patients Remaining Distant Metastases-Free/Alive at 1yr and 2yrs After Initial Treatment

The cumulative percentage of patients remaining distant metastases-free/alive at 1yr and 2yrs after initial treatment

Time frame:
Up to 24 months
Reported as:
Number · Percentage of Participants
Cumulative Percentage of Patients Remaining Distant Metastases-Free/Alive at 1yr and 2yrs After Initial Treatment
Percentage of ParticipantsTreatment (Nivolumab)
At 1 year96 (76 to 99)
At 2 years92 (71 to 98)
SecondaryNumber of Adverse Events

Adverse events will be graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Time frame:
Up to 24 months
Reported as:
Number · adverse events
Number of Adverse Events
adverse eventsTreatment (Nivolumab)
Number of Adverse Events79

Adverse events

Collected over Adverse event reporting will begin after study treatment, unless AE/SAE is caused by a study specific screening procedure, and continue until30 days after the last dose of study treatment. Approximately, 4 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Nivolumab)2/26 (7.7%)2/26 (7.7%)16/26 (61.5%)
Most frequent serious events
Most frequent serious events
EventTreatment (Nivolumab)
DeathGeneral disorders2/26
Most frequent other events
Showing 10 of 38
Most frequent other events
EventTreatment (Nivolumab)
FatigueGeneral disorders13/26
RashSkin and subcutaneous tissue disorders11/26
DiarrheaGastrointestinal disorders7/26
PruritusSkin and subcutaneous tissue disorders6/26
HypothyroidismEndocrine disorders3/26
ConstipationGastrointestinal disorders3/26
Gastrointestinal disorders, OtherGastrointestinal disorders2/26
Neutrophil count decreasedBlood and lymphatic system disorders1/26
HyperthyroidismEndocrine disorders1/26
Hot flashEndocrine disorders1/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Nivolumab)
<=18 years0
Between 18 and 65 years19
>=65 years7
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Nivolumab)
Female10
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Nivolumab)
Hispanic or Latino0
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Nivolumab)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White25
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Nivolumab)
United States26
08

Study locations

4 sites
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Columbia University
    New York, New York 10032, United States
  • Univeristy of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2025, 94 months.

Results were first posted in Jun 2026, 6 months after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 94 months is above that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 19, 2018
StartActual
Jan 17, 2018
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Results first posted
Jun 16, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03405155
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Jan 17, 2018
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Results posted
Jun 16, 2026
Last update
Jul 16, 2026

Study contacts

Takami Sato, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion